Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ophthotech Corp    OPHT

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : to Report Second Quarter 2015 Financial Results and Host Conference Call on Wednesday, August 5, 2015

07/29/2015 | 07:31am US/Eastern

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 888-337-8169 (USA) or 719-325-2455 (International), passcode 8617835. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: www.ophthotech.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is (888) 203-1112 (USA Toll Free), passcode 8617835. The audio webcast can be accessed at: www.ophthotech.com.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.


© Business Wire 2015
React to this article
Latest news on OPHTHOTECH CORP
07/29 OPHTHOTECH : to Report Second Quarter 2015 Financial Results and Host Conference..
07/28 OPHTHOTECH : Results of Operations and Financial Condition, Non-Reliance on Prev..
07/21 OPHTHOTECH : Change in Directors or Principal Officers (form 8-K)
07/21 OPHTHOTECH : Announces New Senior Leadership Appointments
06/04 OPHTHOTECH : Submission of Matters to a Vote of Security Holders (form 8-K)
06/03 OPHTHOTECH : to Present at the Goldman Sachs 36th Annual Global Healthcare Confe..
05/20 OPHTHOTECH : Completes Patient Recruitment of the First Phase 3 Pivotal Trial of..
05/17 OPHTHOTECH : Patients Recruited for the 1st Phase 3 Pivotal Trial of Fovista Ant..
05/14 OPHTHOTECH : to Present at the Deutsche Bank 40th Annual Health Care Conference
05/14 OPHTHOTECH : Posts 1st Quarter 2015 Financial and Operating Results
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Income Statement Evolution
More Financials